Journal of Clinical Oncology· 2019Q1· Clinical trial
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- 2,990citations
- Q1SCImago
- 2019year
Short summary
In a Phase II trial of previously treated patients with advanced noncolorectal cancers deficient in DNA mismatch repair (dMMR/MSI-H), pembrolizumab achieved an objective response rate of 34.3%. This indicates significant clinical benefit for this specific patient population.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Pathology and Forensic Medicine
Pathology and Forensic MedicineMedicine